A retrospective study of 145 patients with microsatellite-stable metastatic CRC who had progressed after at least two systemic treatment lines aimed to evaluate whether fruquintinib alone, fruquintinib plus a PD-1 inhibitor, or the combination with radiotherapy improve outcomes in patients who typically derive little benefit from immunotherapy alone. (J Gastrointest Oncol)
Fruquintinib plus immunotherapy evaluated in MSS refractory mCRC
The CRC Digest